Clinical Evaluation of Allogeneic Bone Marrow-derived Dendritic Cells/Tumor Fusion Hybrids in Canine Cancers
Date Issued
2009
Date
2009
Author(s)
Pai, Chien-Chun
Abstract
Dendritic cell (DC)/cancer cell hybrid vaccine has been emphasized as a new and cancer cell-specific therapeutics. However, the relatively low yield efficiency of the DC generation from peripheral blood limits its clinical application. In this study, we have generated over 20 times more DC from bone marrow (BMDC)/mononuclear leucocytes than the peripheral blood source. The allogeneic BMDC were fused with canine transmissible venereal tumor (CTVT) cells to produce the hybrid vaccine, which was injected subcutaneously (SQ) three times with a two-weeks interval near the draining lymph nodes into beagles with CTVTs of 2 cm in diameter. The CTVT-fusion hybrid vaccination program inhibited the tumor growth as early as at the second vaccination. It significantly increased the host immune responses including the increased lymphocytic infiltrations, CTL responses, and MHC I/II expressions on the tumor. It was interesting to find that the NK activity was also enhanced. We then generated the fusion hybrids of allogeneic BMDC/canine oral malignant melanomas from individual canine patients. The melanoma fusion hybrids were given SQ to the original canine patients but after a surgical removal of the melanoma. After the vaccinations, more than half of the cases have shown increased specific immune responses and the survival time were significantly prolonged in comparing to the dogs with the surgery removal only. To conclude, the canine allogeneic BMDC provided us an efficient way to generate the fusion hybrid vaccines that augmented the host immune responses and demonstrated its clinical potentials in treating cancers.
Subjects
BMDC
CTVT
Melanoma
Hybrid vaccines
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-98-R95629013-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):1eb0e4c6c885fb5f95a7cb4923a96504